Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and uk 68798

moxifloxacin has been researched along with uk 68798 in 23 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(uk 68798)		Trials
(uk 68798)		Recent Studies (post-2010) (uk 68798)
3,1575521,69069865199

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)uk 68798 (IC50)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.1455

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (39.13)29.6817
2010's11 (47.83)24.3611
2020's3 (13.04)2.80

Authors

AuthorsStudies
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M1
Keserü, GM1
Nagashima, R; Nishikawa, T; Tobita, M1
Lombardo, F; Obach, RS; Waters, NJ1
Jia, L; Sun, H1
Caron, G; Ermondi, G; Visentin, S1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bradley, JA; Cass, JD; Chen, X; Dahm, CM; Engwall, MJ; Kadyszewski, E; Sun, Z; Zhou, J1
Attevelt, NJ; Beekman, JD; Chiba, K; Sugiyama, A; Takahara, A; Thomsen, MB; Vos, MA1
Beekman, JD; de Boer, TP; Duker, G; Houtman, MJ; Jonsson, MK; Nalos, L; Peschar, M; Rook, MB; Sartipy, P; Thomsen, MB; van der Heyden, MA; van der Nagel, R; van Veen, TA; Varkevisser, R; Vos, MA1
Cools, F; Danhof, M; Gallacher, DJ; Gotta, V; Morissette, P; Sannajust, F; van Ammel, K; van der Graaf, PH; Visser, SA1
Blinova, K; Chan, D; Crumb, WJ; Erato, C; Florian, J; Guo, P; Hong, M; Johannesen, L; Lin, J; Mason, JW; Mutlib, A; Sanabria, C; Stockbridge, N; Stohlman, J; Strauss, DG; Ugander, M; Vicente, J; Waite-Labott, K; Wang, J1
Casarotto, E; Danhof, M; Della Pasqua, O; Dubois, VF1
Castagné, V; Goineau, S1
Blinova, K; Daluwatte, C; Patel, D; Schocken, D; Strauss, DG; Vicente, J; Wu, JC1
Benson, C; Brown, R; Couderc, JP; Darpo, B; Dota, C; Ferber, G; Ferry, J; Jarugula, V; Keirns, J; Ortemann-Renon, C; Pham, T; Riley, S; Sarapa, N; Ticktin, M; Zareba, W1
Aghasafari, P; Bekker, S; Clancy, CE; Dawson, JRD; DeMarco, KR; Jeng, MT; Noskov, SY; Vorobyov, I; Yang, PC; Yarov-Yarovoy, V1
Clausen, C; Cohen, IS; Cui, J; Gao, J; Grinter, SZ; Hou, P; Kang, PW; Liang, H; Lin, Y; Liu, Y; Lu, Z; Ma, Z; Shi, J; Wang, HZ; White, KM; Xu, X; Zhang, G; Zhao, L; Zhao, W; Zou, X1

Reviews

2 review(s) available for moxifloxacin and uk 68798

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.
    British journal of pharmacology, 2015, Volume: 172, Issue:17

    Topics: Animals; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Long QT Syndrome; Male; Moxifloxacin; Phenethylamines; Potassium Channel Blockers; Reproducibility of Results; Sotalol; Sulfonamides; Telemetry; Translational Research, Biomedical

2015

Trials

3 trial(s) available for moxifloxacin and uk 68798

ArticleYear
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
    Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:2

    Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy, Combination; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Heart Rate; Humans; Lidocaine; Long QT Syndrome; Male; Mexiletine; Moxifloxacin; Phenethylamines; Prospective Studies; Sodium Channel Blockers; Sulfonamides; Young Adult

2016
Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs.
    Clinical and translational science, 2019, Volume: 12, Issue:6

    Topics: Action Potentials; Adult; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Induced Pluripotent Stem Cells; Long QT Syndrome; Male; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Primary Cell Culture; Sulfonamides; Toxicity Tests

2019
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:1

    Topics: Arrhythmias, Cardiac; Biomarkers; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Indoles; Ion Channels; Long QT Syndrome; Male; Moxifloxacin; Ondansetron; Phenethylamines; Quinine; Quinolizines; Risk Assessment; Sulfonamides

2020

Other Studies

18 other study(ies) available for moxifloxacin and uk 68798

ArticleYear
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
    Journal of medicinal chemistry, 2002, Aug-29, Volume: 45, Issue:18

    Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2002
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:5

    Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10

    Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
MICE models: superior to the HERG model in predicting Torsade de Pointes.
    Scientific reports, 2013, Volume: 3

    Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes

2013
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
    British journal of pharmacology, 2005, Volume: 146, Issue:6

    Topics: Action Potentials; Animals; Anti-Infective Agents; Area Under Curve; Arrhythmias, Cardiac; Aza Compounds; Cell Line; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Moxifloxacin; Phenethylamines; Potassium Channels, Inwardly Rectifying; Quinolines; Rabbits; Sulfonamides; Telemetry; Treatment Outcome

2005
No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
    British journal of pharmacology, 2006, Volume: 149, Issue:8

    Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Azithromycin; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Electrophysiology; Fluoroquinolones; Heart Block; Heart Rate; Long QT Syndrome; Moxifloxacin; Phenethylamines; Quinolines; Sulfonamides; Torsades de Pointes

2006
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
    British journal of pharmacology, 2012, Volume: 165, Issue:2

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Aza Compounds; Cell Line; Disease Models, Animal; Dogs; Embryonic Stem Cells; Female; Fluoroquinolones; Heart; Heart Block; Humans; Methoxamine; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Piperidines; Potassium Channel Blockers; Pyridines; Quinolines; Rabbits; Sulfonamides; Torsades de Pointes; Ventricular Remodeling

2012
Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.
    British journal of pharmacology, 2016, Volume: 173, Issue:19

    Topics: Animals; Binding Sites; Cells, Cultured; Cisapride; Consciousness; Dogs; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Long QT Syndrome; Male; Models, Animal; Models, Biological; Moxifloxacin; Phenethylamines; Structure-Activity Relationship; Sulfonamides

2016
Proarrhythmic risk assessment using conventional and new in vitro assays.
    Regulatory toxicology and pharmacology : RTP, 2017, Volume: 88

    Topics: Action Potentials; Anti-Arrhythmia Agents; Arsenic; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; Long QT Syndrome; Moxifloxacin; Myocytes, Cardiac; Pentamidine; Phenethylamines; Risk Assessment; Sulfonamides

2017
A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm.
    Circulation research, 2020, 04-10, Volume: 126, Issue:8

    Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotoxicity; Cardiotoxins; Computer Simulation; Drug Discovery; ERG1 Potassium Channel; Female; Humans; Long QT Syndrome; Machine Learning; Male; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Protein Structure, Secondary; Sulfonamides; Topoisomerase II Inhibitors

2020
Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 05-18, Volume: 118, Issue:20

    Topics: Action Potentials; Amino Acid Substitution; Animals; Arrhythmias, Cardiac; Calcium; Dogs; Furans; Gene Expression; Guinea Pigs; Heart Atria; Heart Ventricles; Humans; KCNQ1 Potassium Channel; Moxifloxacin; Myocytes, Cardiac; Oocytes; Patch-Clamp Techniques; Phenethylamines; Potassium; Primary Cell Culture; Pyridines; Pyrimidines; Small Molecule Libraries; Sodium; Sulfonamides; Transgenes; Xenopus laevis

2021